Both Statin, Non-Statin Therapies Effective for Lowering LDL

This article originally appeared here.
Share this content:
Both Statin, Non-Statin Therapies Effective for Lowering LDL
Both Statin, Non-Statin Therapies Effective for Lowering LDL

TUESDAY, Sept. 27, 2016 (HealthDay News) -- Treatments other than statins also can effectively reduce cardiovascular risk, according to a review and meta-analysis published in the Sept. 27 issue of the Journal of the American Medical Association.

Marc Sabatine, M.D., M.P.H., a cardiologist at Brigham and Women's Hospital in Boston, and colleagues analyzed the results of 49 clinical trials. These included 25 clinical trials for statins, as well as trials for heart-healthy diet, ezetimibe, bile acid sequestrants, and ileal bypass surgery. The evidence review also included two trials with PCSK9 inhibitors.

Non-statin therapies reduced cardiovascular risk by 25 percent for each 1 mmol/L decrease in low-density lipoprotein (LDL) cholesterol levels. That was similar to the 23 percent reduction per 1 mmol/L decrease seen with statins like atorvastatin and simvastatin, the researchers said. Ezetimibe reduced cholesterol by about 20 percent, statins by 30 to 50 percent depending on dose, and PCSK9 inhibitors by as much as 60 percent, according to Sabatine. But the different trials showed that each unit of LDL cholesterol removed from the bloodstream protects cardiovascular health, regardless of how.

"There is a linear relationship between what your LDL cholesterol level is and what your risk is of cardiovascular events," Sabatine told HealthDay. "The relationship suggests that lower is better." What's more, the benefits of these therapies stack up if more than one proves effective at lowering a person's cholesterol levels, he added. "The focus really should be not on a particular drug, but on reducing LDL cholesterol. These data show there are multiple interventions that can do that."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »